Innovations for bronchial asthma prevention in children with elevated blood levels of heavy metals

Dr Alevtina A. Akatova, PhD, DSc, Dr Alfiya I. Aminova, PhD, DSc, Professor Olga Yu. Ustinova, PhD, DSc, Dr Olga A. Maklakova, PhD

Introduction. Environmental bronchial asthma (BA) prevention in children is urgent since the disease has a severe course and is conventional treatment resistant.

Purpose. Develop innovative BA prevention methods in children with recurrent bronchitis (RB) in environmentally unfavourable areas.

Material. We examined children aged 3-7 years with RB (non-acute condition) and blood levels of such toxicants as lead, chromium+6, nickel and manganese exceeding reference values by 1.1, 1.2, 1.3 and 1.3-fold, respectively.

Methods. The proposed technology of environmental BA prevention is based on the complex course of the antileukotriene drug Montelukast* (4 mg at bed time, for 6 months), the enterosorbent Enterosgel (1 teaspoon twice daily, an hour before meals for 10 days/month during 3 months) and a hepatoprotective drug (Eslidine or Chophytol).

Results. An examination carried out a year later showed a 2.7-fold reduction in acute conditions. The number of children having 1-2 acute conditions dropped by 1.8 fold. 79% of the children demonstrated a less severe course of the disease cf. initial 13% (p=0.01). We determined the normalisation of immune indicators (total IgЕ levels decreased from 176.3±18.3 to 98.74±15.23 IU/cm3, p=0.025; lymphocyte count - from 3.64±0.12x109/dm3 to 2.5±0.22x109/dm3; IFN-γ - from 5.30±0.23 to 8.30±0.35 pg/ml) and a redox homeostasis improvement (anti-oxidant activity – from 24.1% to 49.1%, p

Source: Excellence in Paediatrics 2011 (Istanbul, 30 November - 3 December) in the appendix to the journal Acta Paediatrica

You are here


Adress: 82 Monastyrskaya St., Perm, 614045, Russia

Tel/Fax: +7(342)237-25-34

Contact us or send us a message